| 摘要 |
Enhanced antiulcer activity is obtained in warm-blooded animals by the concomitant administration of the histamine H2-receptor antagonist, etintidine, and the pepsin complexing agent, pepstatin. Concomitant administration of the two entities reduces the amount of etintidine necessary for effective treatment, thereby decreasing its side effect liability. |
